News & Articles
Latest news and informative articlesNews
Finalised ICH E9(R1) Estimands and Sensitivity Analysis Guidance
Darren Jolliffe revisits Estimands after it’s adoption in November. Find out how we can help.
Growth, a new office and successful software!
It’s been a fantastic year for S-cubed. Read the reviews from our three managing directors in the UK and Denmark.
Nitrosamines, TOPRA, Drug Development News
Nitrosamines, TOPRA, & Drug Development News are the focus for our Q4 Industry Insights
A3 Community MDR Now Launched
S-cubed is pleased to announce the launch of the A3 Community MDR provided free for the benefit of the CDISC user community.
Using Real World Data to Enhance Pharmaceutical Development
Elizabeth Merrall discusses the case for using real world data (RWD) in clinical research.
Pharmaceutical Industry Events this Autumn
We’re at a number of events between now and the end of November, demonstrating our clinical data expertise. Get in touch if you’d like a meeting.
Global Harmonisation of Clinical Trials
Global Harmonisation of Clinical Trials is the latest focus for our quarterly roundup of the regulatory landscape with news from EMA, FDA and ICH
Protocol writing is changing – Estimands (ICH E9(R1))
This month Darren Jolliffe, explains how S-cubed can assist you in applying the forthcoming regulatory guidance ICH E9(R1)
CDISC 360 Project and the A3 Suite
The CDISC 360 Project is a major change in the way we access and use standards. Our A3 Suite is ready and tuned to the vision.
CDISC, PhUSE, DADM – Events Update
It’s been a busy few months for S-cubed. Find out where we’ve been and where we’re going to next.
Statistics and Machine Learning – Cause for concern or excitement?
Statistics and the impact of machine learning get Elizabeth Merrall thinking and considering the future.
Latest News in Clinical Development Practices and Regulations
Our latest Industry Insights focuses on Brexit and news from the regulators around the globe.
10 Years of S-cubed at CDISC: The Interchange 2019
As we head to the CDISC Interchange this week, make sure you see our presentations and meet our team at Stand 11.
S-cubed Announces A3 Informatics Merger and New Partners
S-cubed is pleased to announce that S-cubed and A3 Informatics have merged to bring the A3 Suite of tools inside the S-cubed brand.
Celebrating 10 Years of Regulatory Affairs and Quality Assurance
Regulatory Affairs and Quality Assurance – S-cubed Ltd are 10 years old. Find out about how our team came together and continue to grow.
Data Silos, Demos, Discussions at PhUSE
The latest papers and presentations from PhUSE US Connect in Baltimore and our future events, including CDISC.
Brexit, EMA, FDA & Global Regulatory News
Our first Industry Insights of 2019 focuses on the latest regulatory developments and Brexit.
PhUSE Keynote – A Cautionary Tale
A fascinating talk by the Keynote Speaker, Dr Ahadpour from the FDA on the opioid addiction crisis in the USA.
Regulatory Affairs & Quality Assurance: Copenhagen
Jakob Sandersen reports on the exciting developments at Pharmaceutical Services ApS over the last 15 months.
PhUSE US Connect & CDISC
Learn all about our presentations at PhUSE US Connect in Baltimore and at the CDISC Interchange in Amsterdam
SME Day at EMA – Part 3
The final report on the SME Day at EMA focuses on the Committee for Advanced Therapies, new Medical Devices Regulation and a Brexit update.
Articles
Qlik: S-cubed Commenting Extension
Bohua Li introduces an S-cubed extension for adding user comments in a Qlik Sense application, along with a guide for users to implement the extension themselves.
An overview of PRIME, Breakthrough Therapy & Fast Track procedures
This article provides an overview of PRIME, Breakthrough Therapy and Fast Track regulatory procedures intended to optimise the development of medicines that target an unmet medical need.
Optimising the path to commercialisation; Who can help and when?
Regulatory Affairs Expert Tony Mitchell co-authors a case study for a new IBS Drug This is case study for a joint project S-cubed worked on for a new drug for IBS – PharmaVentures was the lead company and they were providing market valuation expertise, Apex Healthcare...
INDUSTRY INSIGHTS
Sign up to receive our Industry Insights every quarter
Sign up for our newsletter
Download our latest publication
- Nitrosamines
- TOPRA Top Team
- FDA & EMA Marketing Applications
- Expedited Drug Development Programmes